Hepatitis B and C virus and hepatocellular carcinoma

Olubuyide, IO and Aliyu, B Hepatitis B and C virus and hepatocellular carcinoma. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91 (1). pp. 38-41.

Text (4)ui_art_olubuyide_hepatitis_1997.pdf Download (1MB)

Abstract

Antibody to hepatitis C virus (anti-HCV) was detected in 18·7% of patients with hepatocellular carcinoma (HCC) and in 10·9% of controls (P < 0·001). The corresponding prevalences of hepatitis B surface antigen (HBsAg) were 59·3% and 50·0% (P < 0·001). Using patients with non-hepatic disease as controls, stepwise logistic regression analysis indicated that both anti-HCV (odds ratio 6·88%; 95% confidence interval [CI] 1·63–9·77) and HBsAg (odds ratio 6·46; 95% CI 1·68–18·13) were independent risk factors for HCC. Calculation of the incremental odds ratio indicated no interaction between hepatitis B virus (HBV) and HCV. Blood transfusion was a significant risk factor for acquiring HCV infection with odds ratios of 5·48 (95% CI 1·07–29·0) and 2·86 (95% CI 1·31–22·72) for HCC cases and controls, respectively. The mean age of HCC cases with HBsAg and anti-HCV was lower than that of HCC patients with

Actions (login required)

View Item